Tian Zhang, MD

Assistant Professor of Medicine

Member of the Duke Cancer Institute

Campus mail DUMC 103861, Durham, NC 27710

Phone (919) 668-4667

Email address tian.zhang2@duke.edu

Education and Training

Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
M.H.S., Duke University School of Medicine, 2019
M.D., Harvard Medical School, 2009

Grants

NeoImmune NMTNT110
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies
A first in human study of repeat dosing with REGN2810 a fully human antibody to programmed death - 1 (PD-1) as single therapy and in combination with selected
Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma
Immune correlates of immunotherapy responses in renal cell carcinoma
Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)
Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells

Publications

Hwang, Joyce K., Neeraj Agarwal, James Brugarolas, and Tian Zhang. “Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.” Clin Cancer Res 27, no. 1 (January 1, 2021): 5–7. https://doi.org/10.1158/1078-0432.CCR-20-3506.

PMID

33106290

Full Text

Brown, Landon C., Kunal Desai, Tian Zhang, and Moshe C. Ornstein. “The Immunotherapy Landscape in Renal Cell Carcinoma.” Biodrugs 34, no. 6 (December 2020): 733–48. https://doi.org/10.1007/s40259-020-00449-4.

PMID

33048299

Full Text

Kao, Chester, Daniel J. George, and Tian Zhang. “An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).” Oncologist, November 29, 2020. https://doi.org/10.1002/onco.13617.

PMID

33251710

Full Text

Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J. George, Michael R. Harrison, et al. “Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys, November 28, 2020. https://doi.org/10.1016/j.ijrobp.2020.11.059.

PMID

33259932

Full Text

Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.

PMID

33115529

Full Text

Zhang, Tian, Michael R. Harrison, Peter H. O’Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, et al. “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.” Cancer 126, no. 20 (October 15, 2020): 4485–97. https://doi.org/10.1002/cncr.33067.

PMID

32757302

Full Text

Dinan, Michaela A., Mihaela V. Georgieva, Yanhong Li, Tian Zhang, Michael Harrison, Rahul Shenolikar, and Charles D. Scales. “Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.” J Geriatr Oncol, September 7, 2020. https://doi.org/10.1016/j.jgo.2020.08.005.

PMID

32912737

Full Text

Msaouel, P., A. O. Siefker-Radtke, R. Sweis, S. Mao, J. E. Rosenberg, U. N. Vaishampayan, A Rezazadeh Kalebasty, et al. “705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC).” In Annals of Oncology, 31:S556–S556. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.777.

Full Text

Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.

PMID

32392161

Full Text

Zhang, Tian, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, et al. “Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.” Oncoimmunology 9, no. 1 (June 10, 2020): 1773200. https://doi.org/10.1080/2162402X.2020.1773200.

PMID

32923131

Full Text

Tian Zhang, MD

Education and Training

Grants

Publications

Pages